Castle Biosciences Inc
NASDAQ:CSTL

Watchlist Manager
Castle Biosciences Inc Logo
Castle Biosciences Inc
NASDAQ:CSTL
Watchlist
Price: 26.83 USD -1% Market Closed
Market Cap: 751.5m USD
Have any thoughts about
Castle Biosciences Inc?
Write Note

Net Margin
Castle Biosciences Inc

2%
Current
-33%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
2%
=
Net Income
6.1m
/
Revenue
311.9m

Net Margin Across Competitors

Country US
Market Cap 750.6m USD
Net Margin
2%
Country US
Market Cap 75.6B EUR
Net Margin
1%
Country US
Market Cap 77.9B USD
Net Margin
1%
Country US
Market Cap 56B USD
Net Margin
1%
Country DE
Market Cap 26B EUR
Net Margin
3%
Country DE
Market Cap 18.9B EUR
Net Margin
-2%
Country US
Market Cap 19.3B USD
Net Margin
3%
Country US
Market Cap 17.7B USD
Net Margin
-2%
Country US
Market Cap 17.1B USD
Net Margin
9%
Country DE
Market Cap 13B EUR
Net Margin
3%
Country US
Market Cap 12.7B USD
Net Margin
7%
No Stocks Found

Castle Biosciences Inc
Glance View

Market Cap
750.6m USD
Industry
Health Care

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company is headquartered in Friendswood, Texas and currently employs 342 full-time employees. The company went IPO on 2019-07-25. The company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. The firm markets five multi-analyte assays with algorithmic analysis (MAAA) tests for use in the dermatologic, ocular and gastroenterology fields: DecisionDx-Melanoma, DecisionDx-SCC, Comprehensive Diagnostic Offering (CDO), DecisionDx-UM and TissueCypher Barrett’s Esophagus Assay. DecisionDx-Melanoma is risk stratification gene expression profile (GEP) test developed to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. DecisionDx-SCC, a 40-gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of squamous cell carcinoma (SCC) metastasis for patients with one or more risk factors.

CSTL Intrinsic Value
15.59 USD
Overvaluation 42%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
2%
=
Net Income
6.1m
/
Revenue
311.9m
What is the Net Margin of Castle Biosciences Inc?

Based on Castle Biosciences Inc's most recent financial statements, the company has Net Margin of 2%.